Patents Represented by Attorney, Agent or Law Firm J. W. Appleman
  • Patent number: 6518282
    Abstract: There is provided a compound of formula I, wherein R1, R2, R3 and R4 have meanings given in the description, which are useful in the prophylaxis and in the treatment of pruritus.
    Type: Grant
    Filed: May 23, 2000
    Date of Patent: February 11, 2003
    Assignee: Pfizer Inc.
    Inventors: Stephen Paul Gibson, Ivan Tommasini
  • Patent number: 6333326
    Abstract: This invention relates to 2,3(1H,4H)-quinoxalinedione derivatives which are selective antagonists of N-methyl-D-aspartate receptors. More particularly, this invention relates to 5-triazolyl-2,3(1H,4H)-quinoxalinedione derivatives and to the preparation of, compositions containing, and the uses of, such derivatives. It also relates to a method for treating acute neurodegeneration disorders and chronic neurological disorders.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: December 25, 2001
    Assignee: Pfizer Inc
    Inventors: Alan Stobie, Elisabeth Colette Louise Gautier, David Charles Waite, Robert James Crook
  • Patent number: 6117874
    Abstract: This invention relates to novel benzopyran and other benzo-fused leukotriene B.sub.4 (LTB.sub.4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds, and to a method of using such compounds as LTB.sub.4 antagonists. The compounds of this invention inhibit the action of LTB.sub.4 and are therefore useful in the treatment of LTB.sub.4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfusion injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.
    Type: Grant
    Filed: February 1, 1999
    Date of Patent: September 12, 2000
    Assignee: Pfizer Inc.
    Inventors: Mark Anthony Dombroski, Kevin Koch, Anthony Daniel Piscopio
  • Patent number: 5945118
    Abstract: This invention relates to (R)-5-(aminosulphonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole and its pharmaceutically acceptable salts. This compound is particularly useful in treating disorders arising from deficient serotonergic neurotransmission, especially migraine.
    Type: Grant
    Filed: October 7, 1997
    Date of Patent: August 31, 1999
    Assignee: Pfizer Inc
    Inventors: Martin James Wythes, Paul Morgan